Impact of KIR and HLA Genotypes on Outcomes after Reduced-Intensity Conditioning Hematopoietic Cell Transplantation
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Sep 01, 2015
- Source ID
- 10.1016/j.bbmt.2015.05.002
Entities
People
- Ann Woolfrey
- Carlheinz Müller
- Carolyn Hurley
- Daniel J Weisdorf
- James Gajewski
- Jason Dehn
- Jeffrey Milller
- Karl-johan Malmberg
- Katharine C Hsu
- Marcelo Fernandez-viña
- Marilyn Pollack
- Martin Bornhäuser
- Medhat Askar
- Meighan M. Gallagher
- Michael Haagenson
- Michael R Verneris
- Minoo Battiwalla
- Olle Ringden
- Peter E Shaw
- Ronald M. Sobecks
- Stella Davies
- Stephanie J. Lee
- Stephen R. Spellman
- Susana Marino
- Tao Wang
- Yoshihiro Inamoto
Organizations
- ARIAD Pharmaceuticals
- Actinium Pharmaceuticals (United States)
- Amgen
- Blue Cross Blue Shield Association
- Celgene
- Elevance Health, Inc.
- Fred Hutchinson Cancer Center
- GSK
- Health Research
- HistoGenetics (United States)
- Incyte
- Kiadis Pharma (Netherlands)
- Leukemia & Lymphoma Society
- Medical College of Wisconsin
- Merck & Co.
- Miltenyi Biotec
- National Cancer Institute
- National Heart, Lung, and Blood Institute
- National Institute of Allergy and Infectious Diseases
- National Marrow Donor Program
- Office of Naval Research
- Onyx Pharmaceuticals
- Osiris Therapeutics
- Otsuka (United States)
- Roche (United States)
- Roswell Park Comprehensive Cancer Center
- Sanofi-Aventis
- Seagen
- Sigma-Tau Pharmaceuticals (United States)
- St. Baldrick's Foundation
- StemCyte
- Swedish Orphan Biovitrum
- Tarix Orphan (United States)
- Terumo BCT (United States)
- University of Minnesota
- University of Utah